Enumerating and analyzing circulating tumor cells (CTCs)-cells that have been shed from primary solid tumors-can potentially be used to determine patient prognosis and track the progression of disease. There is a great challenge to create an effective platform that can isolate these cells, as they are extremely rare: only 1-10 CTCs are present in a 7.5mL of a cancer patient's peripheral blood. We have developed a novel microfluidic system that can isolate CTC populations label free. Our system consists of a multistage separator that employs inertial migration to sort cells based on size. We demonstrate the feasibility of our device by sorting colloids that are comparable in size to red blood cells (RBCs) and CTCs.
Introduction
A current focus in microfluidics has been to develop a platform that can isolate circulating tumor cells (CTCs) from the peripheral blood of patients with solid tumors [1] . CTCs are cells that are shed from a primary solid tumor and enter the vasculature. The leading hypothesis is that they play a key role in the metastatic progression of cancer. Very little is known about them, as they are extremely rare: only 1-10 cells per 7.5 mL of patient peripheral blood. The ability to isolate these rare cells with high purity and high recovery would represent a significant advance in cancer screening and monitoring.
Current techniques for isolating and identifying CTCs rely either on the physical properties of these cells (e.g. size, buoyant density, charge, cellular mass, and deformability [2] [3] [4] [5] ) or on the expression of particular markers, such as EpCAM, in combination with CK8, 18, and/or 19. Since CTCs are larger than red blood cells (RBCs, ~ 6 µm), isolation based on cell size via membrane filters [6] has been a large focus.
We have developed a microfluidic device, shown in Figure 1 , which employs inertial migration to manipulate cell streamlines with respect to cell diameter. This technique utilizes two basic concepts: equilibrium and kinematic separation [7, 8] . In equilibrium separation, cells occupy unique equilibrium positions that are dependent on cell properties, such as size. In kinematic separation, secondary flows that are perpendicular to the primary flow direction are employed to manipulate cells to maintain different positions [9] . Under these working concepts, we demonstrate that our device is able to achieve high throughput and label-free sorting.
Theory and Device Design
Our microfluidic device utilizes a balance of inertial lift and Dean drag forces to focus cells into the desired equilibrium positions during fluid flow [10] . In order to separate larger cells (i.e. cancer cells >15 µm) selectively, we employ a two-stage process, shown in 
where, , a, W, ρ, Um, Dh, and µ are the dimensionless lift coefficient, cell diameter, channel width, fluid density, maximum velocity, hydraulic diameter, and fluid viscosity. The shear gradient lift force, , acts to push cells toward the channel walls and is defined by,
As shown in Figure 2 , cells that are randomly dispersed at the microfluidic inlet are eventually ordered within their respective equilibrium position and re-focused toward the microfluidic walls. -r
In Stage 2 of our device, we utilize both inertial lift ( + ) and Dean drag forces,
where UDean is the transverse velocity by Dean flow, to separate particles based on size. As shown in Figure 3 , Stage 2 consists of a single microchannel that has asymmetrical expansion and contraction regions. This is a direct adaptation of the contraction expansion array (CEA), omitting sheath flow, developed by Lee et al. [11] The abrupt changes in the cross sectional area due to these expansion and contraction areas accelerate and decelerate the flow velocity and induce Dean-like flow. Cells are inertially focused toward Sidewall 1 upon being injected into Stage 2. The net inertial lift force dominates larger-sized cells to Sidewall 1 and to a specific output. In contrast, a Dean-drag force dominates and directs smaller-sized particles to the opposite Sidewall 2 and to a different output. 
Materials and Methods
To demonstrate the functionality of our device, we screened fluorescent beads with nominal diameters of 6 ± 0.9 µm (similar in size to RBCs) and 18 ± 0.7 µm (similar in size to CTCs). The different-sized beads were both screened individually and in a 1:4 (6 µm: 18 µm bead) ratio mixture. To prevent clogging due to clusters of beads, we included in-plane filters that we positioned at the entrance of our devices. The beads were tested in our fabricated microfluidic device with an inlet flowrate of 300µ/min generated by a KDS 210 syringe pump.
Device Fabrication
The microfluidic devices were fabricated using standard soft lithography techniques. Briefly, we created a negative master of our device by first spin-coating a 3" silicon wafer with a 90 µm thick layer of negative photoresist (SU8 3050, Microchem). We then UV-exposed the prepared wafer to our mask, post-exposure baked for 15 minutes, and subsequently developed using SU 8 Developer (Microchem). The completed negative masters were hard baked at 150°C for 30 minutes. Polydimethylsiloxane (PDMS) was prepared at a 9:1 polymer to curing agent ratio, degassed, poured over the mold ,and cured at 85°c for 50 minutes. The cured PDMS cast was removed from the mold and the inlets and outlets were cored with a punch (Harris 1.5mm Core). The cored PDMS cast was treated with oxygen plasma with a Harrick Plasma System (PC-001) for 30 seconds and immediately bonded to a glass slide.
Particle Suspension Preparation
Fluorescent polystyrene beads of 6 ± 0.9 µm (Product No. 36-2, 15%CV, Thermo Fisher) and 18 ± 0.7 µm (Product No. 19096, 4%CV, Bangs Lab) mean diameters were used in all experiments. The 6 µm dry stock beads and the aqueous 18 µm beads were suspended and diluted, respectively, in 0.2% pluronic solution (SigmaAldrich) in phosphate buffer solution (PBS) to prevent particle aggregation. The weight ratio of beads in the suspension was 0.05%. The final concentration of beads was 6.3x10 4 and 3.8x10 4 beads/mL for the 6 µm and 18 µm beads, respectively. Figure 4 shows the bead streamlines and lateral position measurements at the end of the multistage separation device. The lateral position was taken as the distance from one wall of the channel straight microchannel to the particle's position within that channel, as shown in Fig. 4A and B. 18 µm green florescent beads flow in a compact streamline near one wall of the microchannel leading to a collection outlet ( Figure 4A ). In a separate measurement, 6 µm red florescent beads are streamlined near the opposite wall of the microfluidic channel leading to a separate outlet ( Figure 4B ). Time lapse videos were recorded and analyzed, frame by frame, to measure the precise lateral position of beads passing through a device that was 350 µm wide. The 6 and 18 µm beads occupied distinct lateral positions within the channel. The 6 um beads occupied an average lateral position of 150 µm from one wall of the channel. In contrast, the 18 µm beads occupied an average lateral position of 250 µm from the same wall. The distinct cut-off for separation lies at a lateral position of 225 µm ( Figure 4C ).
Results & Discussion
When screening a 1:4 mixture of 6 to 18 µm beads, we successfully sorted the different sized beads, Figure  5 . All 18 µm beads were observed within a confined streamline leading toward the upper outlet while a majority of 6 µm beads went towards the lower outlet. We are currently optimizing the integration of Stage 1 and Stage 2 such that smaller particles (beads, cells) do not escape into wrong outlet.
Conclusions
Although we have demonstrated our device using beads that are comparable in size to RBCs and CTCs, the work we have presented show great promise in the isolation of CTCs from patient blood samples. We should expect high recovery of the rare cells; but purity will still be an issue. In order to deplete the sample of any remaining leukocytes whose size range might overlaps with that of the targeted CTCs, we may be able to utilize immunoaffinity negative selection techniques to remove the contaminating leukocytes. 
